Full metadata record
DC FieldValueLanguage
dc.creatorPérez-Pevida, B. (Belén)-
dc.creatorEscalada, J. (Javier)-
dc.creatorMiras, A.D. (Alexander D.)-
dc.creatorFrühbeck, G. (Gema)-
dc.date.accessioned2021-11-03T10:54:34Z-
dc.date.available2021-11-03T10:54:34Z-
dc.date.issued2019-
dc.identifier.citationPérez-Pevida, B. (Belén); Escalada, J. (Javier); Miras, A.D. (Alexander D.); et al. "Mechanisms underlying type 2 diabetes remission after metabolic surgery". Frontiers in Endocrinology. 10 (641), 2019, 641es_ES
dc.identifier.issn1664-2392-
dc.identifier.uri10.3389/fendo.2019.00641-
dc.identifier.urihttps://hdl.handle.net/10171/62305-
dc.description.abstractType 2 diabetes prevalence is increasing dramatically worldwide. Metabolic surgery is the most effective treatment for selected patients with diabetes and/or obesity. When compared to intensive medical therapy and lifestyle intervention, metabolic surgery has shown superiority in achieving glycemic improvement, reducing number of medications and cardiovascular risk factors, which translates in long-term benefits on cardiovascular morbidity and mortality. The mechanisms underlying diabetes improvement after metabolic surgery have not yet been clearly understood but englobe a complex interaction among improvements in beta cell function and insulin secretion, insulin sensitivity, intestinal gluconeogenesis, changes in glucose utilization, and absorption by the gut and changes in the secretory pattern and morphology of adipose tissue. These are achieved through different mediators which include an enhancement in gut hormones release, especially, glucagon-like peptide 1, changes in bile acids circulation, gut microbiome, and glucose transporters expression. Therefore, this review aims to provide a comprehensive appraisal of what is known so far to better understand the mechanisms through which metabolic surgery improves glycemic control facilitating future research in the field.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Institute of Health ISCIII (Subdirección General de Evaluación and Fondos FEDER PI16/01217; Plan Estatal I + D + I/2013–2016). CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) was an initiative of the ISCIII, Spain. The funding source had no role in the writing of the manuscript or the decision to submit it for publication.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media SAes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectType 2 diabetees_ES
dc.subjectBariatric surgeryes_ES
dc.subjectInsulin resistancees_ES
dc.subjectBeta-cell functiones_ES
dc.subjectGlucose absorptiones_ES
dc.subjectGlucose utilizationes_ES
dc.subjectIntestinal gluconeogenesises_ES
dc.subjectHepato-portal glucose sensinges_ES
dc.titleMechanisms underlying type 2 diabetes remission after metabolic surgeryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.es_ES
dadun.citation.number641es_ES
dadun.citation.publicationNameFrontiers in Endocrinologyes_ES
dadun.citation.startingPage641es_ES
dadun.citation.volume10es_ES

Files in This Item:
Thumbnail
File
fendo-10-00641.pdf
Description
Size
554.65 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.